Clinical Research Oversight
All cancer clinical research conducted at Mount Sinai is overseen by The Tisch Cancer Institute (TCI). Cancer-related protocols are required to be reviewed by the Protocol Review and Monitoring Committee (PRMC). Only PRMC approved trials are accepted for review by the Mount Sinai Institutional Review Board (IRB). In addition, the TCI offers protocol-specific research support, intended to support pilot, phase I and phase II trials developed at Mount Sinai which otherwise are unfunded or underfunded from traditional sources.
To ensure that clinical interventional trials in the TCI are initiated and conducted with attention to data safety and monitoring, and as part of the overall data safety and monitoring plan (DSMP), a Data and Safety Monitoring Committee (DSMC) has been established.